Angelman Syndrome Foundation opener
  • Walk
  • Contact Registry
  • News
  • Blog
DOnate
  • What is Angelman Syndrome
    • Symptoms and Causes
    • Testing and Diagnosis
    • Genetics of AS
    • Photo Gallery
  • For Parents
    • Newly Diagnosed
    • Accomplishments of Individuals
    • Participate in Research Studies
    • Angelman Therapeutics
  • Research
    • ASF Funded Research
    • Call for Proposals
    • Current Research Studies
    • LADDER
    • Research Funding Philosophy
  • Make an Impact
    • ASF Cure Club
    • Ways To Donate
    • Fundraise
    • Committees & Groups
    • Send Encouragement
    • Shop & Support ASF
    • Volunteer Opportunities
  • Clinics
    • Find a Clinic
    • Clinic Patient Survey
    • For Clinicians
    • Jacob Pritzker Fellowship Program
    • FAQs
  • Resources
    • Search by Topic
    • Adult Resources
    • ASF Family Resource Team
    • ASF Family Fund
    • ASF Family Champions
    • Angelman Syndrome A to Z
    • ASF Podcast
    • Behavior Resources
    • Communication Resources
    • Counseling Services
    • Educational Webinars
    • Federal Resources
    • IEP Resources
    • International AS Resources
    • Medical Resources
    • Seizures
    • Sibling Programs
    • State Resources
  • Events
    • ASF Walk
    • Conferences and Symposia
    • Bank of America Chicago Marathon
  • About
    • Contact ASF
    • Contact Registry
    • Our Partners
    • Board of Directors
    • Communication Advisory Committee
    • Financial Transparency
    • History of ASF and Angelman Syndrome
    • Parent Advisory Committee
    • Scientific Advisory Committee
    • Receive Texts & Emails
    • Privacy

articles and announcements

Categories: Topoisomerase Inhibitors

January 23, 2020

Epigenetic regulation of Ube3a by a candidate Angelman syndrome drug (UNCilencer1)

$110,000 The ASF Joseph Wagstaff Postdoctoral Research Fellowship was granted to its first recipient.  Dr. King will do his postdoctoral research on a new drug UNCilencer1, which turns on the silenced paternal UBE3A gene in mouse neurons.  UNCilencer1 is a […]

Read more
Ben Philpot, PhD
December 22, 2019

Novel therapeutics for Angelman syndrome by manipulating Ube3a expression

$199,972 (2-year award) Funding for this grant is an attempt to promote research targeted to identifying agents or druggable compounds that may increase expression of UBE3A in brain neurons. Using multidisciplinary facilities, advanced genetic engineering and robotic drug analysis, this grant […]

Read more
December 22, 2019

Association of Sleep and Behavior in Children with Angelman Syndrome

$25,000 – RDCRN Training Grant This proposal seeks to compare the yield of routine EEGs obtained as a standard in the Angelman Natural History protocol with two other types of EEG recordings to identify common EEG patterns. These patterns include […]

Read more
Dr. Mark Zylka
December 21, 2019

Molecular mechanisms and biomarkers of a candidate Angelman syndrome therapeutic

$200,000 – 2-years Dr. Zylka’s lab will expand on the work previously funded by ASF that led to the identification of a family of topoisomerase inhibitors that can unsilence the paternal UBE3A gene.  In order to learn more about this […]

Read more
Ben Philpot, PhD
December 21, 2019

Preclinical testing of a candidate Angelman syndrome therapeutic

$200,000 – 2-years This grant represents a continuation of funding for this investigator’s laboratory which was instrumental in identifying that a class of topoisomerase inhibitors can unsilence the paternal UBE3A gene.  The investigator now plans to extend this work by […]

Read more

Recent Posts

  • GFAS Ukraine and ASF partner to Launch Clinic in Ukraine
  • AngelmanUK and ASF partner to launch clinics in the UK
  • LADDER Database Receives Transformational Dataset from Ovid Therapeutics
  • ASF Partners with Families in UAE to Expand Clinical Network
  • ASF to Host Screening of Caregiver Documentary, Unseen

Browse

  • What is Angelman Syndrome
  • For Parents
  • ASF Funded Research
  • Make an Impact
  • Events
  • About
  • Angelman Resources & Education
  • Contact Registry
  • News
Address Angelman Syndrome Foundation
3015 E. New York Street
Suite A2 #285
Aurora, IL 60504
Phone800.432.6435 Emailinfo@angelman.org

Connect

  • facebook
  • twitter
  • linkedin
  • instagram
  • pinterest
  • rss
  • youtube

The Mission

The mission of the Angelman Syndrome Foundation is to advance the awareness and treatment of Angelman syndrome through education and information, research, and support for individuals with Angelman syndrome, their families and other concerned parties. We exist to give all of them a reason to smile, with the ultimate goal of finding a cure.

  • 4-star charity navigator logo
  • Combined Federal Campaign logo
  • Community Congress logo
Copyright © 2023 Angelman Syndrome Foundation. ALL Rights Reserved. | Site design: BRAND INSPIRATION, LLC